Participated · Series A · Apr 2026

Agriodor develops a class of crop protection solutions that use semiochemicals to influence insect behavior by replicating natural plant scents. Its R&D platform combines high-throughput chemical ecology and reverse chemical ecology to design blends that attract, repel, or disrupt pest insects while preserving beneficial species. The company launched its first commercial product targeting sugar beet aphids and has an exclusive distribution agreement with Syngenta, with an initial field deployment in France. Agriodor is expanding its product portfolio to address additional insect families including fruit flies, whiteflies, and thrips. Founded in 2019 as a spin-off from INRAE by Alain Thibault and Dr Ené Leppik, the company plans to use the Series A funding to accelerate international expansion and wider deployment of its olfactory biocontrol technology.

Led · Equity · Nov 2025

Founded in 2020 as a spin-off from École Normale Supérieure – PSL and the CNRS, Paris-based Hummink has created High-Precision Capillary Printing (HPCaP) technology that deposits metals and functional materials with nanometre accuracy, operating like a miniature fountain pen. The system is intended to complement traditional lithography by detecting and repairing microscopic defects in real time, reducing yield loss and material waste in markets such as semiconductor packaging, next-generation memory, and OLED displays. Its first commercial product, the NAZCA demonstrator, is already generating revenue and is installed in research labs across Europe, Asia, and the United States, including Duke University. Hummink claims its solution can recover a portion of the estimated €16 billion in annual losses from OLED display scrap, where up to 30 % of panels are discarded due to micro-defects. The company also supplies custom conductive inks tailored to its tools, further diversifying its income. Proceeds from the latest funding will be used to develop an industrial printing module and prepare integration into full-scale semiconductor and display fabrication lines.

Led · Equity · Oct 2025

Founded in 2017, London-based nPlan has assembled what it calls the world’s largest dataset of 750,000 completed project schedules worth more than $2.5 trillion across 10 countries. Its deep-learning platform generates probabilistic forecasts that surface hidden risks before they cause costly delays, a capability the company says has already saved clients over $1.2 billion on active projects valued above $500 billion. Flagship customers include Chevron, Shell, MTR Hong Kong, NEOM, HS2, Network Rail, the Transpennine Route Upgrade and Anglian Water. Beyond its core risk-prediction engine, nPlan has launched Barry (an AI decision-support assistant), Schedule Studio (a generative AI tool that turns scope documents into full schedules in seconds), Insights Pro (forecasting and risk management) and nPlan Portfolio (portfolio-level risk analysis). The new capital will expand the London headquarters and grow the footprint in North America, the Middle East and Asia-Pacific while accelerating R&D in predictive and generative AI. Notable angel backers include Sir Demis Hassabis, Sir Ian Davis and Lord David Prior, and earlier institutional investors include GV, Pentech Ventures and LocalGlobe.

Led · Series A · Oct 2025

Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos engineers bacteriophage (phage) treatments through a proprietary platform that combines microbiology with artificial intelligence. Its patented AI analyses complete phage and bacterial genomes to predict interactions and design precise, adaptable therapies as pathogens evolve. The company’s first commercial focus is veterinary medicine, where it has already secured regulatory authorisation to market personalised phage-based treatments aimed at reducing antibiotic use in livestock. Longer term, Phagos intends to expand these solutions to human health applications. With antimicrobial resistance driving millions of deaths and heavy economic costs, management positions the technology as a scalable global standard for bacterial infection control. The recent €25 million Series A financing provides capital to scale veterinary product deployment, advance the next generation of its AI, and grow the team to support market launches and international expansion. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Equity · Nov 2024

Faircraft develops lab-grown leather derived from animal skin cells using proprietary tissue-engineering and cellular agriculture techniques to replicate the structure and composition of traditional leather. The company operates development and manufacturing laboratories at its Paris headquarters and holds two international patents for its standardized, in‑house production process. Faircraft emphasizes luxury finishing, working with master tanners to adapt the material for premium leather goods. Current manufacturing costs remain higher than traditional leather, but the company says it is on a trajectory toward price parity. The $15.8 million funding will be used to expand the team—notably hiring more engineers and biologists—and to accelerate scaling of operations to meet growing demand.